Stratos Wealth Partners LTD. Has $121,000 Holdings in Haleon PLC Sponsored ADR (NYSE:HLN)

Stratos Wealth Partners LTD. lowered its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 26.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,807 shares of the company’s stock after selling 4,202 shares during the period. Stratos Wealth Partners LTD.’s holdings in Haleon were worth $121,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in HLN. Bartlett & CO. Wealth Management LLC lifted its stake in Haleon by 135.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company’s stock valued at $27,000 after buying an additional 1,491 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of Haleon in the 1st quarter valued at approximately $29,000. FIL Ltd lifted its stake in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company’s stock valued at $39,000 after buying an additional 1,270 shares in the last quarter. Continuum Advisory LLC boosted its stake in Haleon by 152.4% in the 1st quarter. Continuum Advisory LLC now owns 4,753 shares of the company’s stock worth $49,000 after purchasing an additional 2,870 shares during the period. Finally, Alpine Bank Wealth Management acquired a new stake in shares of Haleon in the 1st quarter valued at about $56,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HLN has been the topic of several recent research reports. Morgan Stanley upgraded shares of Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price target on the stock in a research note on Friday, May 9th. Barclays reissued an “overweight” rating on shares of Haleon in a research report on Tuesday, May 6th. BNP Paribas Exane raised shares of Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 target price for the company in a research report on Tuesday, May 27th. BNP Paribas upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, May 27th. Finally, Wall Street Zen downgraded shares of Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Stock Down 1.1%

HLN stock opened at $9.59 on Friday. The company has a quick ratio of 0.78, a current ratio of 0.98 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $43.06 billion, a PE ratio of 24.58, a P/E/G ratio of 2.80 and a beta of 0.25. The stock’s 50 day moving average is $10.62 and its 200-day moving average is $10.16. Haleon PLC Sponsored ADR has a twelve month low of $8.80 and a twelve month high of $11.42.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.